New shot aims to control stubborn hepatitis b virus
NCT ID NCT06115993
Summary
This early-stage study is testing a new injectable drug called AHB-137 for people with chronic Hepatitis B. It first checks if the drug is safe in healthy volunteers, then gives it to Hepatitis B patients who are already on stable antiviral pills. The main goal is to see if adding AHB-137 can further reduce or even clear the virus from the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanfang Hospital, Southern Medical University
Guangzhou, China
-
The First Hospital of Jilin University
Jilin, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
Conditions
Explore the condition pages connected to this study.